ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
/
RSS Feed
Jack Cuzick
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071214_jack_cuzick.mp3]
You may also like...
Is breast cancer screening oversold? 29 Mar, 2013 - Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results 28 Jun, 2010
- Lowering hematocrit below 45 per cent protects against clotting risk in patients with polycythemia vera — randomized study finding 11 Dec, 2012
Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML 10 Dec, 2007
